Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies.
2021Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
supportedmidmoderate inflation risk
Subdoligranulum
inflammatory bowel disease
Subdoligranulum is an interesting but still moderate-confidence signal in inflammatory bowel disease.
Subdoligranulum shows a moderate evidence base in inflammatory bowel disease, with multiple central papers and additional supporting literature.
subdoligranulum
Credibility score
21
Human translation
4/5
Reproducibility
3/5
Novelty
4/5
Actionability
2/5
Credibility 21Human translation 4/5Reproducibility 3/5Novelty 4/5Actionability 2/5
Why this scores the way it does
- moderate central evidence base
Main caveats
- directionality and confounding still require curated review
Primary central evidence
8 papersFecal microbiota profile in patients with inflammatory bowel disease in Taiwan.
2021Journal of the Chinese Medical Association : JCMA
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbial butyrate capacity is reduced in inflamed mucosa in patients with ulcerative colitis.
2024Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbial Disruptions in Inflammatory Bowel Disease: A Comparative Analysis.
2024International journal of general medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
[1]The human gut microbiota in IBD, characterizing hubs, the core microbiota and terminal nodes: a network-based approach.
2025BMC microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
New potential biomarkers of ulcerative colitis and disease course - integrated metagenomic and metabolomic analysis among Polish patients.
2025Journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Predicting Risk of Post-Treatment Relapse in Patients with Inflammatory Bowel Disease Based on Intestinal Microbiota.
2025Journal of inflammation research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota composition and function are associated with anxiety and depression in patients with inflammatory bowel disease.
2025PloS one
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
3 papersCombined analysis of metagenomic data revealed consistent changes of gut microbiome structure and function in inflammatory bowel disease.
2021Journal of applied microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Heat-Killed Bifidobacterium bifidum B1628 May Alleviate Dextran Sulfate Sodium-Induced Colitis in Mice, and the Anti-Inflammatory Effect Is Associated with Gut Microbiota Modulation.
2022Nutrients
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut Microbiota Profile Changes in Patients with Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease: A Metagenomic Study.
2024International journal of molecular sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.